

WEBINAR - GSASA CONGRESS

Nanoparticles as Innovative Drug Delivery System

10th NOVEMBER 2022, 12:30 - 13:10 | MESSE LUZERN | LIVESTREAM

**6.25 FPH
Credits***



Specificity of mechanosensitive
liposomes: current and future challenges

Dr med. Thierry Fumeaux, CEO & CMO, Acthera
Therapeutics Ltd, Basel.



Advances in nanomedicine design:
multidisciplinary strategies for unmet
medical needs

Dr Peter Wick, Head Particles-Biology Interactions,
Empa, Swiss Federal Laboratories for Materials Science
and Technology, St-Gallen.




LIVESTREAM
VIA TEAMS

REGISTER NOW

*Only credits in hospital pharmacy

ABSTRACT



PART 1 - 20 MIN.

Specificity of mechanosensitive liposomes: current and future challenges.

Dr Thierry Fumeaux, CEO & CMO, Acthera Therapeutics Ltd, Basel.

Acthera Therapeutics is a Basel-based biotech startup, developing a unique type of mechano-sensitive hard-shelled liposomes (HSL), enabling the controlled and targeted delivery of drugs. The HSL release their cargo when submitted to mechanical stress, such as pathological shear stress, or generated by external triggers such as laser or ultrasound. By combining various types of active pharmaceutical ingredients (small molecules, nucleic acids, biologics) with this unique characteristic of the HSL, Acthera is developing a platform with a high potential to increase the efficiency of drugs in various therapeutics areas.

Developing a platform based on a lipid nanotechnology is however a complex project, with many challenges for a small company. Dr Fumeaux, the CEO of Acthera, will address some of these challenges associated with R&D focusing, regulation, manufacturing upscaling & formulation, but also with funding & financing and partnership identification.

PART 2 - 20 MIN.

Advances in nanomedicine design: multidisciplinary strategies for unmet medical needs.

Dr Peter Wick, Head Particles-Biology Interactions, Empa, Swiss Federal Laboratories for Materials Science and Technology, St-Gallen.

Nanomedicine, the use of nanoscaled material in medicine, has a tremendous impact on innovative health solutions beyond solid lipid-based mRNA vaccines. Nanotechnology allows the first time the design of nanomaterials which are at the same size scale as the building blocks of life, proteins, membrane or DNA. This enables unprecedented opportunities to interfere diseases at the place of origin. This talk will provide some background knowledge about the history, concepts, developments but also the challenges of this rather new research and therapy field.

ABOUT THE SPEAKER




Thierry Fumeaux is a Swiss physician, holding an EMBA from IMD Lausanne, and former adjunct Professor of Medicine at Geneva University. During his post-graduate training, he worked for 4 years in a research lab at Geneva University, to study the mechanisms of immune suppression in severe infections. He has published several basic research and clinical research papers in peer-reviewed journal, and was also president of the Swiss Society of Intensive Care from 2018 to 2020, strongly involved in the management of Covid-19 pandemic at the country level. As specialist in intensive care medicine and internal medicine, he was the head of the ICU and internal medicine ward in Nyon's hospital for 15 years, before joining Acthera in 2021. After having worked as medical advisor consultant, he took the Chief Medical Officer position in 2021, before becoming the CEO of Acthera in 2022.



Peter Wick heads since 2010 the research laboratory for Particles-Biology Interactions at the Federal Laboratories on Materials Science and Technologies Empa in St. Gallen. He got his PhD degree in 2002 at the University of Fribourg, Switzerland. His general research interest is to study the interactions of nanomaterials with human tissues including barrier tissue in vitro and ex vivo with the purpose to obtain detailed mechanistic understanding about their uptake, accumulation, biotransformation, transport and effect on different types of cells or entire tissue. He has published more than 150 papers, was member of the advisory board of the Swiss Action Plan on Nanomaterials, member of the EDQM working group for NBCs, Editorial Board Member of Nanotoxicology, associated editor of the Journal NanoImpact, member of the Swiss National COVID-19 Science Task Force and coordinator of the Swiss National Contactpointnano.ch.

PRACTICAL INFORMATION



WHEN ?

10 September 2022, 12:30-13:10

WHERE ?

Messe Luzern, Horwerstrasse 87, 6005 Luzern

This is a livestream event during the GSASA Congress 2022

HOW TO REGISTER ?

Please use the link to sign up for the webinar:
www.gsasa-symposium.ch

HOW TO PARTICIPATE ?

After successfully registering online, you will receive during the congress a direct link to access the webinar via your own browser

CONTACT INFORMATION

Alexandre Müller
CSL Vifor
alexandre.mueller@viforpharma.com
+41 79 767 78 03

Stéphane Genoud
CSL Vifor
stephane.genoud@viforpharma.com
+41 58 851 67 92